Dr. Monica Vermani, C. Psych. selected as Top Clinical Psychologist by IAOTP
NEW YORK, NY, UNITED STATES, May 23, 2025 / EINPresswire.com / -- Dr. Monica Vermani, Clinical Psychologist, Author, TEDx Speaker, and mental health advocate, was recently selected as Top Clinical Psychologist for 2025 by the International Association of Top Professionals (IAOTP) for her outstanding leadership, dedication, and commitment to the industry.
Inclusion with the International Association of Top Professionals is an honor in itself; only a few members in each discipline are chosen for this distinction. These special honorees are distinguished based on their professional accomplishments, academic achievements, leadership abilities, longevity in the field, other affiliations, and contributions to their communities. All Honorees are invited to attend the IAOTP annual award gala at the end of this year for a night to honor their achievements.
www.iaotp.com /award-gala
With close to three decades in the field of mental health, Dr. Vermani has proven herself an expert in the field. As a dynamic, results-driven leader, Dr. Vermani is a clinical psychologist, author, and founder of Dr. Vermani Balanced Wellbeing and Start Living Corporate Wellness.
She provides therapy and psychological treatment services through a multifaceted dynamic suite of evidence-based treatment modalities, including Cognitive Behavioral Therapy (CBT), Supportive Psychotherapy, Eye Movement Desensitization and Reprocessing (EMDR), Executive Coaching, and Mindfulness Meditation — Mindfulness-Based Stress Reduction (MBSR), and Mindfulness-Based Cognitive Therapy (MBCT), Breath-Mind-Body Practices.
Dr. Vermani specializes in facilitating treatments to adolescents and adults suffering from trauma/abuse, mood, anxiety, substance addictions and other related conditions and disorders. She also offers crisis management, marriage/couples/family counseling, chronic pain management, self-esteem/assertiveness enhancement, vocational counseling, skill development and professional coaching as well as conducts outpatient/inpatient psychological, vocational and forensic assessments. Dr. Vermani has worked with Canadian Armed Forces and US Military personnel, war veterans and 9/11 first responders in New York City, and brings this depth of experience and understanding of the unique needs and challenges of individuals suffering from PTSD.
Recognizing the important role organizations needed to understand and take on to stem the rising costs of employee absenteeism, Dr. Vermani founded Start Living Corporate Wellness. Start Living Corporate Wellness offers companies of all sizes customizable programs that address issues like employee burnout, communication breakdown, anxiety, conflict resolution, and provide counselling, professional coaching skills and knowledge on a wide range of topics designed to erase the stigma around mental health, including managing stress, mood and anxiety, understanding mental health, health and self-care, anger management and avoiding burnout.
Dr. Vermani is also a published author, with numerous professional journal articles, clinical research studies and media publications on trauma and abuse, mood and anxiety disorders, forensic psychology and attention deficit disorder. She is the author of The PCMAD (Primary Care Mood and Anxiety Diagnoser): The Development of a Diagnostic Tool to Detect Social Anxiety Disorder, Generalized Anxiety Disorder, Panic Disorder, Bipolar Disorder and Depression, LAP LAMBERT Academic Publishing, (2011).
In 2021 she published, A Deeper Wellness, Conquering Stress, Mood, Anxiety and Traumas. This engaging and practical book provides a clear and focused path to healing the past, dealing with the present and building an authentic, connected future —creating for a lasting, deeper wellness.
Before embarking on her career path, Dr. Vermani earned her Bachelor's of Science Degree (B.Sc.) with Honors in Psychology, Sociology, Criminology and Women's Studies from the University of Toronto in 1997. She then earned her Master's in Counseling Psychology Degree (M.A.) in 2001 followed by her Doctor of Psychology in Clinical Psychology Degree (Psy.D.) in 2007, both from Adler School of Professional Psychology. In addition, she is a Certified Coach from Certified Coaches Federation (CCF), a Certified Eye Movement Desensitization & Reprocessing (EMDR) Therapist/Consultant, certified in Reiki – Level I, II, II & Master Level, Certified Breath~Body~Mind Meditation Therapist/Teacher, Mindfulness Professional Training Certification Levels 1,2,3, and she earned a diploma in Assaulted Women's & Children's Counselor/Advocate Program from George Brown College.
Throughout her illustrious career, Dr. Vermani has received many awards and accolades and has been recognized worldwide for her accomplishments. This year she will be considered for the Empowered Woman Award and to be featured in TIP (Top Industry Professionals) Magazine. She will be honored at IAOTP's annual awards gala at the remarkable Bellagio Hotel in Las Vegas this December for her selection of Top Clinical Psychologist for 2025.
The President of the International Association of Top Professionals (IAOTP), Stephanie Cirami, stated: 'Choosing Dr. Vermani for this honor was an easy decision for our panel to make. She is inspirational, influential, and a true visionary and thought leader. We cannot wait to meet her and celebrate her accomplishments at this year's gala.'
Looking back, Dr. Vermani attributes her success to a strong values-based leadership style, a passion for her work, and mentors she had along the way. When not working, she enjoys traveling,volunteering, and spending time with friends and family. In the future, she hopes to empower people going into the field.
For more information please visit: https://www.drmonicavermani.com/ and https://www.adeeperwellness.com/dr-vermani
About IAOTP
The International Association of Top Professionals (IAOTP) is an international boutique networking organization that handpicks the world's finest, most prestigious top professionals from different industries. These top professionals are given an opportunity to collaborate, share their ideas, be keynote speakers, and to help influence others in their fields. This organization is not a membership that anyone can join. You have to be asked by the President or be nominated by a distinguished honorary member after a brief interview.
IAOTP's experts have given thousands of top prestigious professionals around the world, the recognition and credibility that they deserve and have helped in building their branding empires. IAOTP prides itself to be a one-of-a-kind boutique networking organization that hand picks only the best of the best and creates a networking platform that connects and brings these top professionals to one place.
For More information on IAOTP please visit: www.iaotp.com
Stephanie Cirami
IAOTP
+1 212-634-4427
email us here
Legal Disclaimer:
EIN Presswire provides this news content 'as is' without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
42 minutes ago
- Yahoo
United Therapeutics Corporation (UTHR) Launches First UKidney Human Trial
We recently compiled a list of United Therapeutics Corporation stands sixth on our list and has launched the first UKidney human trial. United Therapeutics Corporation (NASDAQ:UTHR) is a biotechnology company focused on treating rare, life-threatening diseases such as pulmonary arterial hypertension (PAH) and advancing technologies to address the shortage of transplantable organs. As the first major biotech to become a Public Benefit Corporation, it combines innovation with social impact, especially in organ transplantation. In 2025, the company launched the first human clinical trial of UKidney, a gene-edited pig kidney, in patients with end-stage renal disease (ESRD). The FDA cleared the IND in February, and the first transplant is expected by mid-year. The UKidney features ten genetic modifications to improve human compatibility. The initial trial includes six patients, with plans to expand to 50. United Therapeutics Corporation (NASDAQ:UTHR), often cited among the most undervalued stocks in the biotech industry, is investing $100 million in expanding its Silver Spring, Maryland, organ production campus. This facility will drive large-scale manufacturing of bioengineered organs, leveraging work by its subsidiary, Revivicor, which has already achieved successful pig-to-human organ transplants. In parallel, the business continues advancing therapies for PAH and pulmonary hypertension. It completed enrollment in its TETON-2 trial (inhaled treprostinil for idiopathic pulmonary fibrosis) with results expected later in 2025, and is progressing with other investigational drugs like rilaprag. A biotechnologist in a lab coat discussing a therapeutic antibody with a colleague. By pioneering xenotransplantation and expanding infrastructure, United Therapeutics Corporation (NASDAQ:UTHR) aims to revolutionize organ transplantation and significantly reduce the gap between organ supply and demand. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Fehler beim Abrufen der Daten Melden Sie sich an, um Ihr Portfolio aufzurufen. Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten Fehler beim Abrufen der Daten
Yahoo
42 minutes ago
- Yahoo
California doctor sued for ‘wrongful death' after shipping abortion drugs interstate in legal first
A Texas man is suing a doctor in California he claims mailed his girlfriend pills to end her pregnancy - in what may be a legal first - and a test of new state abortion laws. Jerry Rodriguez filed a wrongful death lawsuit against Remy Coeytaux, after the doctor sent the abortion-inducing drugs across state lines in order to 'murder his unborn son,' Rodriguez claimed. It appears to be the first time an interstate lawsuit for wrongful death over an abortion has been filed, according to The Washington Post. In Texas, a person who assists a pregnant woman in obtaining a self-managed abortion commits the crime of murder and can be sued for wrongful death, the lawsuit, filed in Texas federal court and obtained by The Independent, states. The woman herself cannot be prosecuted. The suit adds it is also a state jail felony for anyone other than a Texas-licensed physician to provide an abortion-inducing drug for the purpose of inducing an abortion. 'In violation of these and many other laws, defendant Remy Coeytaux mailed abortion-inducing drugs into Texas that were used to murder Jerry Rodriguez's unborn child,' the complaint reads. Rodriguez is suing Coeytaux for $75,000 over what he claims is wrongful death. He's also seeking an injunction to stop the doctor from distributing abortion-inducing drugs in violation of state or federal law. The injunction, the suit states, is being sought 'on behalf of a class of all current and future fathers of unborn children in the United States.' But such state legislation clashes with that of California, which retains a so-called 'Shield Law' to protect medical professionals such as Coeytaux. The law provides that 'California will not deliver a person accused or charged with committing a crime related to abortion/gender-affirming care over to law enforcement officials.' This includes situations where a California-licensed pharmacist dispenses an abortion-inducing drug mifepristone to a patient in a state with abortion-restrictive laws. According to Rodriguez's suit, he began dating his girlfriend in June 2024, while she was separated from her husband, but not yet divorced. The Independent has chosen not to name the woman, due to privacy reasons and because she is not a defendant in the lawsuit. The suit alleges that the woman's husband, Adam Garza, twice ordered the abortion medication from Coeytaux after she became pregnant by Rodriguez 'with the intent of using them to murder Mr. Rodriguez's unborn child,' and 'pressured her' to take the pills. A Venmo receipt confirming Garza's purchase of the drugs from Coeytaux was included in the lawsuit, with a reference of ''Aed axes' – allegedly a homonym for 'Aid Access,' an organization that ships abortion-inducing drugs into jurisdictions where abortion is not legal. 'Defendant Coeytaux caused the death of Mr. Rodriguez's unborn child through his wrongful acts,' the lawsuit states. 'Although [the woman] cannot be charged with murder for her role in killing her unborn child, her immunity does not shield Coeytaux from liability for aiding or abetting or directly participating in the murder.' 'Mr. Rodriguez seeks this injunction on behalf of a class of all current and future fathers of unborn children in the United States.' The Independent has reached out to Dr Remy Coeytaux for comment on the lawsuit.
Yahoo
an hour ago
- Yahoo
Vertex Pharmaceuticals Incorporated (VRTX) Launches JOURNAVX, First Non-Opioid Acute Pain Treatment
We recently compiled a list of Vertex Pharmaceuticals Incorporated stands second on our list and has recently launched the first non opioid acute pain treatment. Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), a global biotech firm based in Boston, is known for developing innovative treatments for serious diseases like cystic fibrosis, sickle cell disease, and beta thalassemia. The company is recognized for its strong pipeline targeting unmet medical needs. In July 2025, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) launched JOURNAVX (suzetrigine), a first-in-class, non-opioid treatment for moderate-to-severe acute pain. JOURNAVX, an oral NaV1.8 pain signal inhibitor, was named a 2025 Breakthroughs Innovation Celebration winner by Premier, Inc. It represents the first new class of pain medicine in decades and offers a safer alternative to opioids by directly targeting pain pathways without addiction risks. This launch marks a major advancement in pain management, aligning with public health efforts to reduce opioid use. JOURNAVX is especially relevant for acute pain scenarios such as post-surgical recovery and injury care. A closeup of pills in a pharmacy, representing the high quality medications of the company. Beyond acute pain, Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) continues to expand its reach. Its next-gen cystic fibrosis therapy, ALYFTREK, received approval from the European Commission in July 2025, strengthening its global leadership in this area. The company is also advancing gene-editing therapies like CASGEVY for sickle cell and beta thalassemia, and is developing treatments for kidney disease, type 1 diabetes, and rare genetic disorders. While we acknowledge the potential of GOOGL as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Sign in to access your portfolio